



Evogene Financial Results and Earnings Announcement Schedule for the Fourth Quarter and Full Year of 2020

Rehovot, Israel – February 17th, 2021 – Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the fourth quarter and full year of 2020 on Wednesday, March 3rd, 2021. Dr. Arnon Heyman, Chief Executive Officer of Evogene's medical cannabis subsidiary, Canonic Ltd., will join the conference call to discuss Canonic's activity.

On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com.

A replay of the conference call will be available approximately two hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5901 internationally. The replay will be accessible through March 5th, 2021, and an archive of the webcast will be available on the webcast link for the following twelve months.

-xxx-

About Evogene Ltd.:

Evogene (NASDAQ: EVGN), (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Castera Ltd. For more information, please visit www.evogene.com.



Evogene Investor Contact:

Aviva Banczewski / Rivka Neufeld
Investor Relations and Public Relations Manager
E: IR@evogene.com
T: +972-8-931-1900

US Investor Relations:

Joseph Green
Edison Group
E: jgreen@edisongroup.com
T: +1 646-653-7030

Laine Yonker
Edison Group
E: lyonker@edisongroup.com
T: +1 646-653-7035